Elafibranor for previously treated primary biliary cholangitis (TA1016)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 November 2024
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 June 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2020
Obeticholic acid for treating primary biliary cholangitis (TA443)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2017
Everolimus for preventing organ rejection in liver transplantation (TA348)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
Seladelpar for previously treated primary biliary cholangitis [ID6429]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 20 August 2025Expected publication date: 5 November 2025
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 6 January 2027
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC